首页> 外文期刊>Frontiers in Pharmacology >Corrigendum: Anakinra Therapy for Non-cancer Inflammatory Diseases
【24h】

Corrigendum: Anakinra Therapy for Non-cancer Inflammatory Diseases

机译:更正:Anakinra治疗非癌性炎症性疾病

获取原文
           

摘要

In the original article “Anakinra Therapy for Non-cancer Inflammatory Diseases”, we failed to provide citations for publications relevant to the discovery of IL-1Ra. The citations have now been inserted in the Introduction , Historical Background of IL-1 and IL-1Ra and should read: “As stated in our review (Cavalli and Dinarello, 2018 ), in 1981 we described a circulating suppressor factor from humans during experimental endotoxemia as assayed for specific inhibition of IL-1 activity in vitro (Dinarello et al., 1981 ). We believe this circulating suppressor factor was the first description of IL-1Ra, and we confirmed our findings in a report published in Lancet in 1991 using a specific radioimmunoassay for IL-1Ra (Granowitz et al., 1991 ). However, in 1984, there was documentation from the group of Jean-Michel Dayer describing a specific inhibitor of IL-1 activity isolated from the urine of patients with monoblastic leukemia (Balavoine et al., 1984 ). This was an essential contribution to the history of the discovery of the antagonist. In 1985, there was another report from the Dayer laboratory “Collagenase- and PGE2-Stimulating Activity (Interleukin-1-Like) and Inhibitor in Urine from a Patient with Monocytic Leukemia”, as published in Progress in Leukocyte Biology , vol. 2 (New York, NY: Alan R. Liss, 1985 p. 429). These reports were followed by another publication in the Journal of Clinical Investigation (Balavoine et al., 1986 ). As stated in our Review, “the IL-1 inhibitor” isolated from the urine was shown to prevent binding of IL-1 to cells (Seckinger et al., 1987 ), thus providing for the first time evidence for its mechanism of action. Because of the widespread and beneficial use of anakinra (the recombinant form of the nature IL-1Ra) to treat human diseases, the contributions of Jean-Michel Dayer as well as those of William Arend are paramount.” The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
机译:在原始文章“用于非癌性炎症性疾病的阿纳金拉疗法”中,我们未能提供与发现IL-1Ra有关的出版物的引用。现在已将这些引文插入到《 IL-1》和《 IL-1Ra的引言,历史背景》中,并应注明:“正如我们的评论所述(Cavalli和Dinarello,2018年),1981年,我们描述了实验过程中人体内循环抑制因子如对内毒素血症的体外IL-1活性的特异性抑制进行测定(Dinarello等,1981)。我们认为这种循环抑制因子是对IL-1Ra的首次描述,我们在1991年《柳叶刀》杂志上发表的一篇针对IL-1Ra的特异性放射免疫分析法中证实了我们的发现(Granowitz等,1991)。然而,在1984年,让-米歇尔·戴耶(Jean-Michel Dayer)组的文献描述了一种从单细胞白血病患者的尿液中分离出来的IL-1活性的特异性抑制剂(Balavoine等,1984)。这是对拮抗剂发现历史的重要贡献。 1985年,Dayer实验室的另一份报告《单核细胞白血病患者尿液中的胶原酶和PGE2刺激活性(白细胞介素-1样)和抑制剂》发表在《白细胞生物学进展》第一卷中。 2(纽约,纽约:Alan R. Liss,1985年第429页)。这些报告之后,又在《临床研究杂志》上发表了另一篇文章(Balavoine等,1986)。如我们的综述所述,从尿液中分离出的“ IL-1抑制剂”被证明可以防止IL-1与细胞结合(Seckinger等,1987),从而首次为其作用机理提供了证据。由于Anakinra(IL-1Ra的自然重组形式)在人类疾病中的广泛和有益的应用,让-米歇尔•戴耶(Jean-Michel Dayer)和威廉•阿伦德(William Arend)的贡献至关重要。作者对此错误表示歉意,并声明这不会以任何方式改变本文的科学结论。原始文章已更新。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号